NCT06598956View on ClinicalTrials.gov

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 12, 2024

Primary Completion Date

March 17, 2025

Study Completion Date

August 12, 2025

Conditions
Myelofibrosis
Interventions
DRUG

TQ05105

TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.

Trial Locations (1)

250000

The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital), Jinan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY